Company intelligence / Profile preview
Thios Pharmaceuticals
Emeryville, California, United Statesthiospharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Thios Pharmaceuticals developed therapies targeting biological sulfation pathways, with a lead program focused on an adhesion-blocking antibody for chronic inflammatory diseases. The company in‑licensed TS1 (rPSGL-Ig), a clinical-stage compound from Wyeth, intended for acute sickle cell disease crises and prevention of delayed graft function post-kidney transplant. The company is now out of business and did not advance any products to market.
- Therapeutic areas
- PulmonologyHematologyOncologyNephrologyImmunology
- Modalities
- Monoclonal antibodyHumanized single-chain antibody fragmentSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Wyeth (licensing agreement for TS1/rPSGL-Ig)
Beyond the preview
Go deeper on Thios Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thios Pharmaceuticals.